Where there is risk there is reward and nowhere does this apply more than to biotechnology companies. Mark Dunne puts the sector under the microscope and discovers a quintet of portfolio-enhancing firms.
We use cookies to ensure that we give you the best experience on our website.
If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website.
You may change your preferences at any time.
